Candel Therapeutics (CADL) AI Stock Analysis

• Market Cap: $364.04M
• Dividend Yield: N/A
• Average Volume (3M): 1.43M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: N/A
• EPS Growth: 68.53%
• Country: US
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.54
• Shares Outstanding: 73,246,925
• 10 Day Avg. Volume: 1,447,619
• 30 Day Avg. Volume: 1,429,429
• PEG Ratio: 0.13
• Price to Book (P/B): 5.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.69
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -183.47
• Enterprise Value/Ebitda: -3.27
• 1Y Price Target: $19.40
• Price Target Upside: 290.34% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -1.26
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $5.00 ▲(0.60% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and sustained cash burn) and bearish-to-neutral technical momentum (below key moving averages with negative MACD). Positive financing events improve funding runway and balance-sheet flexibility, but they do not fully offset the current lack of operating profitability and negative cash flow.

Positive Factors

Extended cash runway into Q1 2028

Having cash and expected proceeds that extend runway into Q1 2028 materially lowers near-term financing pressure and gives management time to complete pivotal readouts, a BLA submission, and pre-commercial activities. This durable liquidity supports execution of multi-quarter clinical and launch milestones.

Non-dilutive royalty funding for launch

The $100M royalty facility is structured to provide launch financing without upfront dilution, activating on FDA approval. That aligns external capital to commercialization outcomes and preserves equity until approval, providing a durable, conditional funding source for launch activities.

Meaningful debt reduction and stronger capital base

Sharp decline in leverage and a positive equity base materially improve financial flexibility and reduce interest/credit strain. A stronger balance sheet supports sustained investment in late-stage trials and launch readiness and is a durable foundation for 2-6 month operational plans.

Negative Factors

Effectively zero revenue and persistent operating losses

With no meaningful product revenue and large recurring operating losses, the company cannot internally fund development or commercialization. This structural lack of operating income forces reliance on external capital and magnifies downside if clinical or regulatory setbacks occur.

Consistent negative operating and free cash flow

Sustained cash burn means recurring financing is required to progress programs. This ongoing negative cash flow increases execution risk, ties management to capital markets cyclicality, and could force program pacing or partnership dependence absent successful commercialization.

Reliance on dilutive equity raises for funding

Large public equity offerings provide needed capital but dilute existing shareholders and can erode per-share economics over time. Dependence on dilution to fund operations increases shareholder dilution risk and ties long-term returns to successful clinical/commercial execution.

Candel Therapeutics Business Overview & Revenue Model

Company Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

How the Company Makes Money

As a clinical-stage biotechnology company, Candel Therapeutics does not have publicly established recurring product sales from approved therapies; therefore, revenue is not primarily generated from commercialized drugs (null). The company’s funding and reported income have typically come from financing activities (e.g., issuing equity and other capital-raising transactions) used to support research and development and clinical trials (null). Any additional potential revenue sources—such as collaboration payments, licensing revenue, milestone payments, royalties, or government grants—are not reliably available here as specific, current, and attributable details for CADL; thus, detailed identification of key revenue streams and significant partnerships contributing to earnings is null.

Candel Therapeutics Financial Statement Overview

Summary

Financial performance is weak overall: the company has effectively zero revenue, persistent large operating losses (e.g., EBIT -$48.3M in 2025), and consistent negative operating/free cash flow (FCF about -$39.0M in 2025). The main offset is balance-sheet improvement with sharply reduced debt and positive equity, but returns remain poor in loss years.

Income Statement

The income statement remains weak and typical of an early-stage biotech: revenue is effectively zero across the period (with only minimal revenue in 2020–2022 and none in 2023–2025), while operating losses are sizable and persistent (EBIT of -$48.3M in 2025 vs. -$33.4M in 2024). Profitability is not established, with recurring net losses in most years provided (e.g., -$55.2M in 2024, -$37.9M in 2023). A modest positive is that 2025 shows net income reported at 0, but the continued large operating loss suggests underlying profitability has not improved materially.

Balance Sheet

The balance sheet is comparatively stronger than the earnings profile. Leverage has improved meaningfully, with total debt down to ~$1.9M in 2025 from ~$22.8M in 2022 and ~$22.8M in 2023, and debt-to-equity declining to ~0.04 in 2025 (from ~1.79 in 2023). Equity is positive and sizable in recent years ($51.9M in 2025; $66.3M in 2024), and total assets have increased to ~$125.2M in 2025 from ~$41.2M in 2023. The key weakness is that returns on equity are poor/negative in the loss years (e.g., 2024 return on equity of about -0.83), indicating the capital base is not yet generating earnings.

Cash Flow

Cash flow quality is pressured by consistent cash burn. Operating cash flow is negative every year shown (e.g., -$38.3M in 2025, -$27.0M in 2024, -$34.2M in 2023) and free cash flow is also consistently negative (e.g., -$39.0M in 2025). Free cash flow did improve in 2025 versus 2024 (growth of ~15.3%), but the business still requires ongoing funding to support operations. The relationship between cash flow and net income is not a clear strength here because net income is negative in several years (and is 0 in 2025), making “cash flow relative to earnings” less informative for comfort on sustainability.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	125.00K	125.00K
Gross Profit	-845.00K	-990.00K	-23.98M	125.00K	-14.47M
EBITDA	-47.42M	-52.10M	-37.43M	-16.31M	-25.49M
Net Income	-38.18M	-55.18M	-37.94M	-18.79M	-36.12M
Balance Sheet
Total Assets	125.19M	106.87M	41.20M	78.52M	89.20M
Cash, Cash Equivalents and Short-Term Investments	119.73M	102.65M	35.41M	70.06M	82.64M
Total Debt	1.90M	13.47M	22.76M	22.80M	560.00K
Total Liabilities	73.27M	40.54M	28.46M	30.80M	25.07M
Stockholders Equity	51.92M	66.33M	12.74M	47.71M	64.14M
Cash Flow
Free Cash Flow	-38.90M	-27.04M	-34.70M	-32.72M	-24.05M
Operating Cash Flow	-38.31M	-27.02M	-34.24M	-31.42M	-22.22M
Investing Cash Flow	-560.00K	-16.00K	-280.00K	-1.30M	-1.83M
Financing Cash Flow	56.10M	94.28M	-121.00K	19.97M	71.80M

Candel Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CADL, the sentiment is Negative. The current price of 4.97 is below the 20-day moving average (MA) of 5.02, below the 50-day MA of 5.52, and below the 200-day MA of 5.53, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 44.89 is Neutral, neither overbought nor oversold. The STOCH value of 52.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CADL.

Candel Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLUE	54 Neutral	$1.25B	-33.72	-15.12%	―	1112.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNXP	51 Neutral	$201.08M	-1.07	-60.15%	―	-8.79%	81.36%
CADL	47 Neutral	$364.04M	―	-51.44%	―	―	68.53%
QSI	46 Neutral	$182.85M	-3.09	-43.90%	―	40.20%	-4.07%
HUMA	45 Neutral	$151.10M	-3.93	853.54%	―	―	82.23%
INBX	42 Neutral	$889.86M	―	-269.56%	―	―	―

Candel Therapeutics Corporate Events

Candel Therapeutics Announces Equity Offering to Fund CAN-2409

On February 19, 2026, Candel Therapeutics, Inc. entered into an underwriting agreement to sell 18,348,624 shares of common stock at $5.45 per share, with underwriters granted a 30-day option to buy up to an additional 2,752,293 shares. The registered offering, led by Citigroup, Cantor Fitzgerald, and Stifel, is expected to close on or about February 23, 2026, subject to customary conditions.

Candel expects approximately $93.5 million in net proceeds from the base offering, or up to about $107.6 million if the option is fully exercised, and plans to deploy the capital toward launch readiness, medical affairs, pre-commercialization, and commercial activities for CAN-2409 in early localized prostate cancer, as well as continued funding of the phase 3 trial of CAN-2409 in non-small cell lung cancer and general corporate purposes. Based on assumed net proceeds of $93.5 million, the company estimates its cash and cash equivalents will fund operating and capital needs into the first quarter of 2028, extending its runway and supporting late-stage development and potential commercialization efforts.

The most recent analyst rating on (CADL) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.

Candel Therapeutics Secures $100M Royalty Funding for CAN-2409

On February 19, 2026, Candel Therapeutics announced a $100 million royalty-based funding agreement with funds managed by RTW Investments to support the potential U.S. launch of its lead candidate aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, contingent on future FDA marketing approval. Under the deal, RTW will receive tiered single-digit royalties on U.S. net sales of CAN-2409 up to a $250 million cap, while Candel, which estimated unaudited cash and cash equivalents of about $119.7 million as of December 31, 2025, strengthens its balance sheet with non-dilutive capital ahead of a planned biologics license application submission in the fourth quarter and positions itself for a first commercial entry in a prostate cancer segment that has seen limited innovation in two decades.

The transaction includes provisions for a buy-out option if Candel undergoes a change of control or sells CAN-2409 rights, allowing termination of the royalty agreement for specified payments up to the cap. The structure, which activates only upon regulatory approval and other closing conditions, underscores RTW’s confidence in the commercial potential of CAN-2409 following pivotal phase 3 data in early localized prostate cancer and aligns investor and company interests around execution of a U.S. launch strategy.

The most recent analyst rating on (CADL) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.